Garadacimab Reduces HAE Attacks Significantly, Preliminary Phase 2 Trial Results Show
Preliminary results from a Phase 2 clinical trial testing the investigational therapy garadacimab for the treatment of hereditary angioedema (HAE) show a more than 88% reduction in the number of attacks, the therapy’s developer CSL Behring announced. The…